Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™ and cisplatin: A multicenter phase II trial

摘要: Summary Background To evaluate the activity of MTA plus cisplatin in chemotherapy-naive patients with non-small cell lung cancer (NSCLC). Patients and methods Thirty-six NSCLC received 500 mg/m2 75 mg/m2cisplatin every 21 days, 4 mg dexamethasone orally twice daily on day before, of, after administration. Results Median age was 58 years. WHO performance status 0–2. Eighteen each had stage IIIB IV disease. Seventeen squamous-cell adeno-carcinoma; two undifferentiated Fourteen (39%; 95% confidence interval: 23%–57%) showed partial response; seventeen (47%) stable survival 10.9 months. Twenty-one (59%) experienced grade 3 or granulocytopenia without fever infection. Five (14%) six (17%) anemia thrombocytopenia, respectively. Nonhematological toxic-ities included nausea (6%), diarrhea one patient (3%) each. One ALT bilirubin AST elevations. Conclusions is well tolerated active against NSCLC. Further studies this combination are warranted.